Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without ipilimumab plus radiation in pretreated metastatic pancreatic or biliary tract cancer
2016-001883-12Phase 2Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic cancer (PC) and biliary cancer comparing Nivolumab + radiation therapy with Nivolumab + ipilimumab + radiation therapy (2 arms). Primary endpoint: Clinical benefit rate. Started Jun 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
pancreatic cancer (PC)biliary cancer
Beyond the preview
Go deeper on 2016-001883-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001883-12.